Bio-Rad Laboratories, Inc. (BIO.B) stock
BIO.BNYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 8/3055% above fair value
$379.50+0.00 (0.00%)
Close on Oct 29, 2026Market cap $10.18BP/E 46.2Yield –
Bio-Rad Laboratories net income
Net income is the profit left for shareholders after every expense, interest and tax.
Bio-Rad Laboratories's net income for the twelve months ending Jun 30, 2026 was $222.40M, down 30.3% year over year. For fiscal 2025 it was $759.90M. Over ten years it grew 21.4% a year on average. The highest annual figure on record is $4.25B in fiscal 2021.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $759.90M | – |
| FY2024 | Dec 31, 2024 | -$1.84B | – |
| FY2023 | Dec 31, 2023 | -$637.30M | – |
| FY2022 | Dec 31, 2022 | -$3.63B | -185.3% |
| FY2021 | Dec 31, 2021 | $4.25B | +11.5% |
| FY2020 | Dec 31, 2020 | $3.81B | +116.9% |
| FY2019 | Dec 31, 2019 | $1.76B | +381.0% |
| FY2018 | Dec 31, 2018 | $365.61M | +199.1% |
| FY2017 | Dec 31, 2017 | $122.25M | +370.2% |
| FY2016 | Dec 31, 2016 | $26.00M | -76.2% |
| FY2015 | Dec 31, 2015 | $109.24M | +23.0% |
| FY2014 | Dec 31, 2014 | $88.85M | +14.2% |
| FY2013 | Dec 31, 2013 | $77.79M | -53.0% |
| FY2012 | Dec 31, 2012 | $165.48M | -7.6% |
| FY2011 | Dec 31, 2011 | $179.01M | -3.5% |
| FY2010 | Dec 31, 2010 | $185.49M | +28.3% |
| FY2009 | Dec 31, 2009 | $144.62M | +61.6% |
| FY2008 | Dec 31, 2008 | $89.51M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $371.40M | +16.9% |
| Q1 FY2026 | Mar 31, 2026 | -$527.10M | -923.6% |
| Q4 FY2025 | Dec 31, 2025 | $720.00M | – |
| Q3 FY2025 | Sep 30, 2025 | -$341.90M | -152.3% |
| Q2 FY2025 | Jun 30, 2025 | $317.80M | – |
| Q1 FY2025 | Mar 31, 2025 | $64.00M | -83.3% |
| Q4 FY2024 | Dec 31, 2024 | -$715.80M | -304.7% |
| Q3 FY2024 | Sep 30, 2024 | $653.20M | +514.5% |
| Q2 FY2024 | Jun 30, 2024 | -$2.17B | – |
| Q1 FY2024 | Mar 31, 2024 | $383.90M | +456.4% |
| Q4 FY2023 | Dec 31, 2023 | $349.70M | -57.8% |
| Q3 FY2023 | Sep 30, 2023 | $106.30M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.16B | – |
| Q1 FY2023 | Mar 31, 2023 | $69.00M | – |
| Q4 FY2022 | Dec 31, 2022 | $827.70M | – |
| Q3 FY2022 | Sep 30, 2022 | -$162.80M | -104.1% |
| Q2 FY2022 | Jun 30, 2022 | -$925.10M | -200.9% |
| Q1 FY2022 | Mar 31, 2022 | -$3.37B | -443.6% |
| Q4 FY2021 | Dec 31, 2021 | -$1.57B | -287.3% |
| Q3 FY2021 | Sep 30, 2021 | $3.93B | +198.9% |
| Q2 FY2021 | Jun 30, 2021 | $916.80M | -5.1% |
| Q1 FY2021 | Mar 31, 2021 | $980.00M | +42.9% |
| Q4 FY2020 | Dec 31, 2020 | $839.20M | +51.6% |
| Q3 FY2020 | Sep 30, 2020 | $1.31B | – |
| Q2 FY2020 | Jun 30, 2020 | $966.40M | +61.4% |
| Q1 FY2020 | Mar 31, 2020 | $685.90M | -20.7% |
| Q4 FY2019 | Dec 31, 2019 | $553.50M | – |
| Q3 FY2019 | Sep 30, 2019 | -$258.80M | -196.1% |
| Q2 FY2019 | Jun 30, 2019 | $598.80M | +123.4% |
| Q1 FY2019 | Mar 31, 2019 | $865.20M | +31.7% |
| Q4 FY2018 | Dec 31, 2018 | -$828.50M | -1101.8% |
| Q3 FY2018 | Sep 30, 2018 | $269.30M | +1118.6% |
| Q2 FY2018 | Jun 30, 2018 | $268.00M | +5260.0% |
| Q1 FY2018 | Mar 31, 2018 | $656.80M | +5196.8% |
| Q4 FY2017 | Dec 31, 2017 | $82.70M | – |
| Q3 FY2017 | Sep 30, 2017 | $22.10M | +29.2% |
| Q2 FY2017 | Jun 30, 2017 | $5.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $12.40M | – |
| Q4 FY2016 | Dec 31, 2016 | -$18.70M | – |
| Q3 FY2016 | Sep 30, 2016 | $17.10M | – |